

REVIEW

Open Access



# Interplay of fatty acids, insulin and exercise in vascular health

Kara C. Anderson<sup>1†</sup>, Jia Liu<sup>1†</sup> and Zhenqi Liu<sup>1\*</sup>

## Abstract

Fatty acid metabolism, exercise, and insulin action play critical roles in maintaining vascular health, especially relevant in metabolic disorders such as obesity, type 2 diabetes, and cardiovascular disease. Insulin, a vasoactive hormone, induces arterial vasodilation throughout the arterial tree, increasing arterial compliance and enhancing tissue perfusion. These effects, however, are impaired in individuals with obesity and type 2 diabetes, and evidence suggests that vascular insulin resistance contributes to the pathogenesis of type 2 diabetes and its cardiovascular complications. Elevated plasma levels of free fatty acids in people with insulin resistance engender vascular inflammation, endothelial dysfunction, and vascular insulin resistance. Importantly, these effects are both functionally and structurally dependent, with saturated fatty acids as the primary culprits, while polyunsaturated fatty acids may support insulin sensitivity and endothelial function. Exercise enhances fatty acid oxidation, reduces circulating free fatty acids, and improves insulin sensitivity, thereby mitigating lipotoxicity and promoting endothelial function. Additionally, exercise induces beneficial vascular adaptations. This review examines the complex interplay among fatty acid metabolism, exercise training-induced vascular adaptations, and insulin-mediated vascular changes, highlighting their collective impact on vascular health and underlying mechanisms in both healthy and insulin-resistant states. It also explores the therapeutic potential of targeted exercise prescriptions and fatty acid-focused dietary strategies for enhancing vascular health, emphasizing tailored interventions to maximize metabolic benefits. Future research should investigate the pathways linking fatty acid metabolism to vascular insulin resistance, with a focus on how exercise and dietary modifications can be personalized to enhance vascular insulin sensitivity, optimize vascular health, and reduce the risks of type 2 diabetes and associated cardiovascular complications.

**Keywords** Endothelial function, Exercise, Fatty acid metabolism, Insulin resistance, Lipotoxicity, Nitric oxide, Tissue perfusion, Type 2 diabetes, Vascular inflammation

<sup>†</sup>Kara C. Anderson and Jia Liu contributed equally to this work.

\*Correspondence:

Zhenqi Liu  
zl3e@virginia.edu

<sup>1</sup>Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

## Introduction

The global rise in the prevalence of type 2 diabetes (T2D) and the associated cardiovascular disease (CVD) morbidity and mortality has made the study of metabolic health and vascular function increasingly critical. Most people with T2D have increased adiposity, elevated plasma free fatty acids (FFAs) and hypertension in addition to dysglycemia [1–3], and eventually succumb to the vascular (both microvascular and macrovascular) complications [4]. Insulin is an anabolic hormone that regulates carbohydrate, protein, and lipid metabolism. Importantly, insulin is also a potent vasoactive hormone and actively modulates vascular tone and tissue perfusion, and vascular insulin resistance has been linked to the pathogenesis of T2D and the associated cardiovascular complications [5–8]. FFAs are essential for normal cellular function and play a pivotal role in the regulation of metabolic homeostasis, not only by serving as key energy sources and cellular structural components, but also critically modulating metabolic signaling pathways, including insulin secretion and action. However, excess availability of fatty acids, especially the saturated fatty acids (SFAs), can disrupt insulin signaling and glucose metabolism and lead to insulin resistance and higher risk of developing T2D and the associated CVD complications [9–11]. The impact of FFAs on insulin action and substrate metabolism is structure and concentration dependent, where polyunsaturated fatty acids (PUFAs) have been shown to enhance insulin sensitivity and attenuate glucose intolerance, and SFAs are linked to insulin resistance and metabolic dysfunction [12]. Exercise plays a foundational role in human health, significantly influencing insulin sensitivity, fatty acid metabolism, and vascular function, and remains one of the most effective non-pharmacological interventions for T2D prevention and management [13–16]. This review explores the intricate relationship among insulin action, fatty acid metabolism, and exercise in metabolic homeostasis and vascular function, with a hope of not only to fill the literature gap but also provide guidance on future studies.

### Insulin action and resistance in the vasculature – implications for metabolic abnormalities and CVD

Insulin is an anabolic as well as a vasoactive hormone. It actively modulates vascular tone to regulate tissue perfusion and insulin's vascular actions closely couple with its metabolic actions [17]. Vascular endothelium expresses abundant insulin receptors as well as the insulin-like growth factor I (IGF-1) receptors and the hybrid insulin/IGF-1 receptors [18–22]. At physiological concentrations, insulin binds and activates the insulin receptors exclusively, but at supra-physiological or pharmacological concentrations, insulin also stimulates the IGF-1 receptors and the hybrid insulin/IGF-1 receptors [18].

In the vasculature, insulin signals mainly through the phosphatidylinositol 3-kinase (PI3K) / Protein kinase B (Akt) / endothelial nitric oxide (NO) synthase (eNOS) pathway to produce NO, which is a potent vasodilator [18, 19, 23, 24], and the mitogen-activated protein kinase (MAPK) / extracellular signal regulated kinase (ERK) pathway to mediate endothelial cell proliferation and the expression and secretion of a vasoconstrictor endothelin-1 (ET-1). ET-1 acts on the G protein-coupled endothelin receptors, mainly the ET<sub>A</sub> and ET<sub>B</sub> subtypes, to engender vasoconstriction, oxidative stress, and vascular smooth muscle cell growth and mitogenesis [25–29]. Insulin exerts actions on all segments of the arterial system, including the conduit arteries, the resistance arterioles, and the microvasculature [30–32]. As each segment of the arterial tree has different structure and function, the results of insulin's actions on the vasculature vary depending on the arterial size and location (Fig. 1) [2, 8, 13, 33].

Conduit arteries are large arteries containing collagen and elastin filaments in the tunica media and expand in response to cardiac ejection to maintain a relatively constant pressure in the arteries [34]. Insulin infusion in healthy humans enhances the responsiveness of the femoral artery to methacholine-induced vasodilation [35] and decreases augmentation index (AI) (i.e., increased distensibility / compliance) [30, 36, 37]. The resistance arterioles, which range from 400  $\mu\text{m}$  to 100  $\mu\text{m}$ , are the major determinant of vascular resistance and total tissue blood flow [38]. Insulin infusion dilates resistance arterioles, and results in decreased vascular resistance and increased total tissue blood flow in humans [35, 39–43]. The microvasculature, including small arterioles, capillaries, and small venules, plays a pivotal role in maintaining tissue health by delivering adequate supply of oxygen, nutrients, and hormones to the tissues and removing metabolic waste and by-products away from the tissues. Over the past two decades, the actions of insulin on the microvasculature have garnered high attention as numerous studies have confirmed that muscle microvasculature is an insulin target, insulin is an important physiological modulator of muscle microvascular perfusion, and there is a close coupling between insulin-mediated microvascular perfusion and insulin-stimulated glucose disposal in the skeletal muscle [5, 17]. Insulin-mediated muscle microvascular recruitment occurs within 5–10 min and this precedes insulin-stimulated glucose disposal in muscle which occurs in ~20–30 min, and inhibition of NO synthesis during insulin infusion via eNOS inhibition abolishes insulin-induced microvascular recruitment in muscle and reduces insulin-stimulated muscle glucose disposal by up to 40% [44, 45].

Insulin's actions on different arterial segments are interconnected either directly or indirectly. We have

Vessel	Conduit Arteries	Resistance Arterioles	Microvasculature
Function	<ul style="list-style-type: none"> <li>• Regulation of intra-arterial pressure</li> <li>• Regulation of total blood flow</li> </ul>	<ul style="list-style-type: none"> <li>• Regulation of vascular resistance</li> <li>• Regulation of blood flow to terminal tissues</li> </ul>	<ul style="list-style-type: none"> <li>• Perfusion of tissues</li> <li>• Exchange of oxygen and substrates</li> </ul>
Insulin	<ul style="list-style-type: none"> <li>• ↑ Compliance</li> </ul>	<ul style="list-style-type: none"> <li>• ↓ Vascular resistance</li> <li>• ↑ Blood flow</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ Tissue perfusion</li> <li>• ↑ Exchange of oxygen and substrates</li> </ul>
Exercise	<ul style="list-style-type: none"> <li>• ↑ Compliance</li> <li>• ↑ Vascular remodeling</li> </ul>	<ul style="list-style-type: none"> <li>• ↑↔ Blood flow</li> <li>• ↑ Vascular remodeling</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ Tissue perfusion</li> <li>• ↑ Substrate exchange</li> <li>• ↑ Capillary density</li> <li>• ↑ Capillary to fiber ratio</li> </ul>
Insulin Resistance & Endothelial Dysfunction	<ul style="list-style-type: none"> <li>• ↑ Arterial stiffness</li> <li>• ↑ Atherosclerosis</li> <li>• ↓ Endothelium-dependent vasodilation</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ Peripheral resistance</li> <li>• ↓ Blood flow</li> <li>• ↑ Blood pressure</li> </ul>	<ul style="list-style-type: none"> <li>• ↓ Tissue perfusion</li> <li>• ↓ Capillary density</li> <li>• ↓ Substrate exchange</li> </ul>
Surrogate Index Examples	<ul style="list-style-type: none"> <li>• FMD</li> <li>• PWV</li> <li>• AI</li> </ul>	<ul style="list-style-type: none"> <li>• Forearm strain-gauge plethysmography</li> <li>• FMD</li> </ul>	<ul style="list-style-type: none"> <li>• Contrast-Enhanced Ultrasound (cardiac and skeletal muscle)</li> </ul>

**Fig. 1** Vascular function and the impact of insulin and exercise. Vascular function varies depending on vessel size and location. Insulin and exercise lead to beneficial effects throughout the vasculature, while insulin resistance and endothelial dysfunction impair vascular function. (Abbreviations: FMD, flow mediated dilation; PWV, pulse wave velocity; AI, augmentation index)

previously shown that insulin-enhanced flow-mediated dilation (FMD) is independently associated with insulin-mediated microvascular perfusion in muscle [2]. This is important as FMD reflects endothelial function mainly in the conduit artery (with some component of resistance arterioles) and microvascular perfusion is mostly controlled by resistance and microvascular arterioles. This is also not surprising as both FMD and insulin-mediated microvascular perfusion are predominately NO-dependent [46–48]. In healthy humans and adults with metabolic syndrome, there is a clear correlation between FMD and insulin-mediated glucose disposal during the insulin clamp [31] while insulin-stimulated glucose disposal and insulin-mediated changes in microvascular perfusion are mutually predictive in a cohort including healthy, obese, and type 1 diabetes populations [49].

It has been well-documented that insulin resistance can occur in all segments of the arterial tree, and vascular insulin resistance typically co-exists with endothelial dysfunction and metabolic insulin resistance. Insulin's vasodilatory action in the conduit arteries and resistance arterioles is clearly impaired in insulin resistant conditions [31, 35, 50] and people with T2D frequently have both impaired endothelium-dependent FMD [51] and reduced insulin-mediated NO-dependent vasodilation [41, 52]. In humans with obesity or metabolic syndrome, there is a marked resistance of the ability of insulin to decrease arterial stiffness [50, 53]. This is very important as reduced compliance of the conduit arteries independently predicts atherosclerotic coronary and cerebral artery diseases [53–56]. Mounting evidence confirms that insulin-mediated microvascular perfusion

in cardiac and skeletal muscle is lost in insulin resistant conditions like obesity and metabolic syndrome [31, 57, 58]. Vascular insulin resistance is also present in the microvasculature in insulin resistant states, and there is clear evidence of generalized microvascular dysfunction in people with prediabetes or T2D [59]. Impaired insulin-mediated microvascular perfusion has been seen in obese and diabetic animals [60, 61], humans with T2D [62], and humans with obesity [58, 63]. Insulin resistance at the microvasculature level appears to be more closely coupled with metabolic insulin resistance as the microvasculature plays a pivotal role in regulating insulin delivery from the circulation to the tissue interstitium [17]. It is important to note that microvascular insulin resistance contributes to the development of systemic insulin resistance and occurs early in the disease course [64]. In mice on a HFD, vascular insulin resistance occurs within one week, while it takes 4–8 weeks to develop in muscle and liver and 14 weeks in adipose tissue [65]. In rats on a HFD, microvascular insulin resistance was observed 3 days after the initiation of the HFD, while impaired insulin-mediated glucose disposal and muscle Akt phosphorylation were not observed until one week after [64]. As such, early intervention that targets microvascular insulin resistance might afford an opportunity to delay the development of systemic insulin resistance and the onset of T2D.

The fundamental pathophysiology of endothelial insulin resistance resides in the PI3K/Akt/eNOS signalling pathway, while the MAPK signalling pathway is spared or even enhanced due to the compensatory insulin secretion [29, 66, 67]. This selective insulin resistance results in a

reduced NO production and amplifies the MAPK-mediated cell proliferation and ET-1 production [68], leading to a decreased vasodilation and increased vascular tone in arterioles with subsequently less tissue perfusion [26, 27] and predisposing affected people to atherosclerosis, hypertension, and/or microvascular complications.

### **Fatty acids, metabolic regulation and insulin action**

In addition to regulating carbohydrate and protein metabolism, vascular tone, and tissue perfusion, insulin also actively regulates lipid metabolism, with an overall effect of increasing fat storage [69–71]. It activates capillary endothelium lipoprotein lipase to hydrolyze circulating lipoprotein triglycerides and generate free fatty acids (FFAs) that are either oxidized by tissue or stored by fat cells. It also facilitates the re-esterification of FFAs into triglycerides within fat cells and inhibits hormone-sensitive lipase, a rate-limiting enzyme in the lipolytic pathway, both of which lead to decreased plasma levels of FFAs.

Fatty acids are a key energy source for cells, particularly during periods of fasting or prolonged physical activity when carbohydrate stores are depleted. In times of increased energy demand, lipolysis occurs to generate FFAs which are transported into cells, and  $\beta$ -oxidized in the mitochondria to generate adenosine triphosphate (ATP) [69, 71]. The balance among fatty acid intake (either from food sources or lipolysis), storage locations (i.e., adipose tissue vs. ectopic storage in muscle and liver), and rate of oxidation is critical for metabolic homeostasis. Chronic elevation of plasma FFA levels, and excess accumulation of fatty acids in tissues other than adipose tissue are associated with insulin resistance, inflammation, and tissue dysfunction [2, 72, 73]. FFAs are perhaps the most important physiological factors that regulate glucose metabolism and insulin action in vivo. FFAs are classified based on the number of double bonds in their hydrocarbon chains. Monounsaturated fatty acids (MUFAs) contain one double bond, and polyunsaturated fatty acids (PUFAs) contain two or more double bonds, while SFAs lack double bonds. Each class of fatty acids has distinct effects on glucose metabolism and insulin secretion and action. Short-term exposure of  $\beta$ -cells to FFAs potentiates glucose-stimulated insulin secretion through GPR40-mediated process [74], and the potency increases with chain length and degree of saturation [75–77]. On the other hand, prolonged exposures of  $\beta$ -cells to fatty acids increases basal insulin release but inhibits glucose-stimulated insulin secretion in vitro [78, 79] as well as in vivo [80, 81]. The prolonged exposure findings are more clinically relevant as plasma FFAs are elevated in people with obesity and insulin resistance / T2D [82], and there is clear evidence of glucolipotoxicity causing  $\beta$ -cell dysfunction [83].

Numerous studies have confirmed a causative effect of FFAs on insulin resistance through mechanisms involving intracellular accumulation of diacylglycerol and ceramide, activation of protein kinase C (PKC), activation of the nuclear factor kappa B (NF- $\kappa$ B) pathway, decreased *PPAR* $\gamma$  coactivator-1  $\alpha/\beta$  activation, recruitment of immune cells like macrophages, neutrophils, and bone marrow-derived dendritic cells to adipose tissue and muscle, and decreased tyrosine phosphorylation of insulin receptor substrate 1/2 [84–89]. However, it is important to note that different FFAs appear to have distinctly different impacts on glucose metabolism. It is well known that SFAs, such as palmitic acid, potently trigger insulin resistance [89–92] while MUFAs, such as oleic acid found in olive oil, have neutral or even beneficial effects on glucose metabolism [89, 93]. A good example is the Mediterranean diet, which is rich in MUFAs. In clinical trials, the Mediterranean-type diet was found to improve glycemia in those with T2D [94], and the risk of T2D was 83% lower among those who closely adhered to the diet [95]. Even among those at high CVD risks and without calorie restriction, the Mediterranean diet seems to be effective in preventing T2D [96]. Whether these beneficial actions are the direct results of unsaturated fatty acids remain to be determined, as in vivo and in vitro evidence has suggested that unsaturated fatty acids also cause insulin resistance [97] despite the experimental evidence of unsaturated fatty acids reducing inflammation and improving insulin sensitivity.

### **Fatty acids, endothelial function, and vascular insulin action**


While the endothelial cells derive their energy primarily through glycolysis [98–100], fatty acid oxidation in endothelial cells critically regulates endothelial function [101]. Equally important is the uptake and transport of fatty acids by endothelial cells to meet the needs of surrounding cells for a variety of cellular processes, including membrane synthesis, intracellular signal transduction, ATP generation, protein posttranslational modifications, and metabolic gene transcriptional regulation [102, 103]. However, abnormalities in lipid and fatty acid metabolism are detrimental to endothelial biology and function [104]. People with T2D frequently manifest lipid abnormalities such as hypertriglyceridemia and elevated levels of plasma FFAs [105], where both are well-established risk factors of CVD.

Endothelial cells take up and metabolize fatty acids through the tricarboxylic acid cycle in the mitochondria to produce ATP and store excess fatty acids as cytosolic lipid droplets, protecting cells from endoplasmic reticulum stress from excess FFAs [106]. When the levels of FFAs surpass the cellular protective capacity, endothelial dysfunction ensues. Multiple mechanisms contribute to

FFA-induced endothelial dysfunction, including oxidative stress, inflammation, cellular apoptosis, impaired insulin signaling, and reduced NO bioavailability [6, 104, 107]. Studies have confirmed a causative role of FFAs in endothelial dysfunction and endothelial insulin resistance, which are closely coupled, mutually perpetuate, and contribute together to accelerate cardiovascular diseases [42, 43, 104, 108, 109]. They are present throughout the arterial tree, and the outcomes differ based on the structure and location of the arteries affected [2]. Thus, endothelial dysfunction and insulin resistance in the conduit arteries accelerate atherosclerosis, in the resistance arterioles elevate blood pressure, and in the microvasculature perturbs glycemia [5, 110–112], all pathophysiological manifestations seen frequently in the setting of T2D (Fig. 1& Fig. 2). Elevated circulating FFA levels (similar to those in the post-absorptive state in T2D [82]

or metabolic syndrome [31]) interfere with shear stress-induced NO production and reduce insulin-mediated vasodilation of the conduit and resistance arteries [42], blunt insulin-induced increases in FMD and reduction in AI [2], as well as induce microvascular insulin resistance in both cardiac and skeletal muscle [2, 108, 109]. Findings of lipid-inducing microvascular insulin resistance were similarly reported in a rodent study [113]. In a multivariate regression analysis, insulin-mediated muscle microvascular perfusion was independently associated with insulin-mediated FMD and pulse wave velocity [2]. Thus, clinically relevant elevation of plasma FFA concentrations induces pan-arterial insulin resistance and the outcomes of insulin resistance in various arterial segment are interconnected.

The raising plasma levels of FFAs reduces NO flux, impairs shear-stress-induced NO production, depresses



**Fig. 2** FFAs impair endothelial function and vascular health. FFAs are released from adipose tissue and enter the bloodstream. Elevated plasma FFAs induce endothelial inflammation through upregulation of inflammatory genes and increased ROS production to promote a selective insulin resistance in the vascular endothelium, resulting in reduced NO bioavailability, increased arterial stiffness and vascular resistance, less tissue perfusion, and reduced capillary substrate supply and exchange. (Abbreviations: FFAs, free fatty acids; ROS, reactive oxygen species; JNK, c-jun N-terminal kinase; IKK $\beta$ , inhibitor of nuclear factor kappa-B kinase subunit beta; NF- $\kappa$ B, nuclear factor kappa-light-chain-enhancer of activated B cells; PPARs, peroxisome proliferator-activated receptors; IRS, insulin receptor substrate; PI3-K, Phosphatidylinositol 3-kinase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; P, phosphorylation.)

methacholine-induced vasodilation which is endothelium-dependent but not nitroprusside-induced vasodilation which is endothelium-independent suggest that NO bioavailability is crucial in FFA-induced endothelial insulin resistance and endothelial dysfunction [42, 43]. While multiple mechanisms could have contributed to FFA-induced reduction in NO bioavailability, the most likely culprit is FFA-induced oxidative stress and vascular inflammation (Fig. 2) [6, 114, 115]. FFAs are important inciters of a chronic, low-grade systemic inflammation state seen in insulin resistant conditions such as obesity, metabolic syndrome and T2D [42, 43, 87, 108, 109, 116, 117]. Multiple signaling pathways and factors seem to have been implicated in this process, including the endoplasmic reticulum stress pathway, PKC pathway, c-Jun NH2-terminal kinase (JNK), toll like receptor 4 (TLR4) pathway, and inhibitor of nuclear factor kappa B (IkB) kinase  $\beta$  (IKK $\beta$ ) [89, 92, 118–121]. Activation of these pathways increases the production of reactive oxygen species (ROS) which reduces NO bioavailability. Additionally, reduced NO production also contributes to low NO bioavailability, as raising plasma FFA concentrations not only decreases shear stress-induced NO production but also blunt insulin-mediated eNOS activation and NO production [2, 104, 122].

FFA-induced oxidative stress and inflammation are crucial in the pathogenesis of endothelial insulin resistance, specifically in the PI3K/eNOS/NO pathway [64, 104, 123], and it appears that the endothelium is more sensitive to FFA insult than other tissues. Feeding mice a HFD for one week decreases insulin signaling in the aorta, while taking 8 weeks to do so in the skeletal muscle [65]. Our data suggest that insulin resistance in the microvasculature occurs even earlier than that in the aorta, as feeding rats a HFD blocks insulin-mediated muscle microvascular recruitment in as early as 3 days [64]. The inflammation-induced microvascular insulin resistance is clearly an early event in diet-induced obesity, as inhibition of the NF $\kappa$ B pathway attenuates microvascular as well as metabolic insulin resistance during HFD feeding [64].

FFAs also contribute to capillary rarefaction, a phenomenon well recognized in the insulin resistant tissues, particularly in the muscle [124–126]. The degree of reduction in muscle capillary density correlates with the severity of insulin resistance [125, 127, 128], possibly through the expression and action of the vascular endothelial growth factor (VEGF) family of proteins [129], which recruit and differentiate endothelial progenitor cells and induce endothelial cell proliferation and migration, leading to new vessel formation [129]. In the insulin resistant state, VEGF action on muscle vasculature is impaired, which triggers muscle capillary regression [124, 130]. We have shown previously that feeding rats a HFD

for 4 weeks reduced muscle VEGF expression as well as muscle capillary density [131]. In vitro cell culture studies have clearly demonstrated that FFAs directly lead to endothelial cell apoptosis. Incubation of endothelial cells with palmitate showed that palmitate dose- and time-dependently induced apoptosis, likely through a p38 MAPK-mediated mechanism [107]. However, it is important to note that not all FFAs trigger endothelial apoptosis. Stearic acid (a SFA), but not oleic acid (a MUFA), time and concentration dependently increases endothelial apoptosis [132].

Together, FFAs-induced endothelial dysfunction, endothelial insulin resistance, and endothelial cell apoptosis contribute to the pathogenesis of metabolic insulin resistance and the associated cardiovascular complications, thus making the vascular endothelium a viable therapeutic target for T2D prevention and management [112]. As currently available evidence, both preclinical and clinical, link excess saturated but not unsaturated fatty acids with the risk of CVD, more studies are needed to optimize dietary fatty acid intake for maintaining a good vascular health.

### **Exercise, fatty acid oxidation, and vascular function**

Exercise engenders myriad metabolic and cardiovascular benefits, and delays the development of T2D [133–136]. Exercise profoundly impacts the vasculature in health and disease by inducing both functional and structural adaptations throughout the arterial tree. For conduit arteries, exercise training improves endothelial dependent dilation, as measured through FMD [137], and this change appears to be magnified in those with endothelial dysfunction [138]. Exercise training also improves conduit artery wall stiffness, particularly with higher aerobic exercise intensity and in participants with greater arterial stiffness at baseline [139]. Structurally, exercise induces local and systemic arterial wall remodeling, with the localized effects more evident in the remodeling of arterial size whereas arterial wall thickness is more affected by systemic factors [140], and the latter appears to be unrelated to exercise type [141]. Exercise-induced improvement in conduit artery endothelial function appear to be mediated through shear stress-induced / Akt-dependent eNOS phosphorylation [142]. However, the exercise-induced changes in shear rate are not obligatory for arterial wall remodeling [143]. Overall, functional adaptations typically precede structural adaptations during exercise training [137]. The results of exercise impact on resistance arteries are inconsistent in healthy individuals, with studies reporting either no change [144, 145] or an improvement [146, 147] in resistance artery endothelial function measured through forearm strain-gauge plethysmography. However, the beneficial effect of exercise

is clearer in individuals with endothelial dysfunction, with an improvement in function and NO bioavailability reported in a variety of clinical populations, including those with T2D [142, 147–149]. As for the microvasculature, exercise is perhaps the most potent known physiological factor that increases microvascular blood flow in the myocardium and skeletal muscle. In the myocardium, exercise augments coronary blood flow via dilatation of the coronary microvessels to meet the increased oxygen demand as oxygen extraction in the coronary circulation is nearly maximal at rest (70–80%) [150]. Even a simple handgrip exercise potently increases microvascular perfusion in the myocardium [151], as well as the skeletal muscle [152] in healthy humans. Importantly, this exercise- / muscle contraction-induced skeletal muscle microvascular perfusion is preserved in humans [153, 154] as well as in rodents [155–157] with insulin resistance. Exercise also potently stimulates muscle angiogenesis [158], and well-trained endurance athletes may have 3–4 times more capillaries per muscle fiber than sedentary individuals [159]. Both shear stress and passive stretch enhance the expression of angiogenic factors and initiation of capillary growth [158, 160, 161]. Among all factors, VEGF is central to exercise-induced muscle capillary growth. In mice with muscle-specific VEGF deficiency, muscle capillary density is reduced by ~50% and endurance running capacity decreases by 80% [162]. Muscle contraction leads to a redistribution of VEGF-containing vesicles toward the sarcolemma and the release of VEGF to the muscle interstitium, which acts on the capillary endothelial VEGF receptors to stimulate the angiogenic process [158]. Exercise also increases VEGF mRNA expression, which allows for replenishment of VEGF stores lost through secretion during exercise [158]. Together, the functional and structural adaptation to exercise training ensures adequate capacity for oxygen and nutrients delivery to the exercising muscle. However, it is important to note that while exercise augments vascular function in both healthy and insulin resistant states, the effect of exercise intensity is equivocal due to differences in exercise protocols and vascular methodology within the existing literature.

Exercise is known to improve insulin sensitivity in both insulin sensitive and resistant states [163]. Even moderate daily exercise can greatly improve insulin sensitivity, and a single bout of exercise increases insulin sensitivity into the next day in humans with obesity [164]. While multiple mechanisms contribute to exercise-mediated insulin sensitization, exercise-induced vascular adaptations, particularly in the microvasculature, play an important role [13]. Increased conduit artery blood flow and reduced resistance in the resistance arterioles result in higher total tissue perfusion, while increased microvascular blood flow leads to more oxygen, nutrients and hormones

delivered to the tissue [165–168]. We have recently determined the phenotypic traits that foretell human muscle microvascular insulin responses using a combination of contrast-enhanced ultrasound and hyperinsulinemic euglycemic clamp in adult humans, with insulin sensitivity spanning from normal to resistance. Among all factors associated with metabolic insulin resistance, we found only peak oxygen uptake ( $VO_{2peak}$ ) predicted insulin-induced changes in muscle microvascular blood volume [49], suggesting a profound impact of exercise capacity on muscle microvascular insulin responses in humans. How exercise attenuates microvascular insulin resistance remains to be clarified. In HFD fed rodents, exercise reduces vascular inflammation, endothelial oxidative stress, perivascular macrophage accumulation, and superoxide production in muscle, along with increased endothelial nucleus translocation of Nrf2 and endothelial AMPK phosphorylation [115]. Additionally, exercise induces increased muscle insulin delivery likely via increased microvascular perfusion and expanded microvascular endothelial surface area available for insulin extraction [155, 169]. Indeed, in rats receiving an insulin infusion, muscle contraction markedly increased interstitial insulin concentrations compared with the non-contracting leg [170].

The exercise induced increase in total tissue blood flow and microvascular perfusion, along with the improvement in microvascular insulin sensitivity in the insulin resistant states, can profoundly affect fatty acid metabolism. Increased total tissue blood flow leads to more FFAs delivered to the muscle, and expanded microvascular endothelial surface area enables more FFAs extracted from the circulation to the muscle interstitium. At rest, skeletal muscle uses lipid oxidation as the primary fuel source (~60%) but with exercise, both fatty acids and glucose are important energy sources for the exercising muscle [171, 172]. However, lower intensity [ $\leq \sim 50\% VO_{2peak}$ ] and prolonged activities rely more on fatty acid utilization while during high intensity exercise lipolysis is inhibited, the availability of FFAs in the blood declines, and the substrate of choice crosses over from fatty acids to carbohydrates [173–175]. This crossover phenomenon is seen in both trained and untrained individuals, with the trained individuals experiencing the shift at a higher intensity level, helping to “spare” carbohydrates and thus delay the depletion of muscle glycogen and development of fatigue during exercise [173, 176]. Studies have shown peak rates of fat oxidation occur at intensities between 59% and 64%  $VO_{2peak}$  in trained individuals and between 47% and 52% of  $VO_{2peak}$  in untrained individuals [177]. In individuals with insulin resistance, fatty acid oxidation increases in response to training in both healthy and T2D populations [178], and the improvement to lipid metabolism in response to exercise, in healthy individuals as well

as those with insulin resistance, appears to be independent of weight loss [179]. While the exact mechanism remains to be defined, exercise potently increases the delivery of fatty acids to skeletal muscle and the proteins involved in lipid metabolism, such as transport proteins CD36, FATP4, and FABPpm [179]. Data also suggest that the ability to efficiently oxidize fatty acids is important for glucose homeostasis. One study showed that preprandial fatty acid oxidation is inversely associated with insulin-stimulated glucose disposal rate during a hyperinsulinaemic-euglycaemic clamp in both healthy individuals and individuals with T2D [180]. Another study found that long-term inhibition of fatty acid oxidation in mice led to hepatic steatosis and whole-body insulin resistance [181]. Therefore, exercise can be a powerful tool to improve insulin sensitivity through enhancing fatty acid oxidation.

Interestingly, studies comparing the effects of high intensity interval training and moderate intensity continuous training have found comparable results regarding fatty acid oxidation [15, 182]. For individuals with insulin resistance, both intensities have been shown to improve fatty acid oxidation and/or markers of oxidative metabolism [183, 184]. From an exercise-induced microvascular perfusion perspective, both low intensity and high intensity muscle contractions are potent in expanding the microvascular blood volume perfusion but higher intensity muscle contraction also increases flow velocity, leading to higher blood flow [152]. Whether this leads to a difference in fatty acid extraction in the microcirculation is not known.

Unlike skeletal muscle, the heart primarily uses long chain fatty acids as a substrate (~70%). However, in diabetic cardiomyopathy, the reliance on fatty acids increases due to dysfunctional glucose oxidation [185]. This leads to increased oxygen consumption and reduced myocardial efficiency [186]. Exercise training has been shown to induce beneficial cardiac remodeling in both healthy and diabetic hearts, including increases in oxidative enzymes and decreased oxidative stress. Further, after treadmill training in diabetic mice, the overreliance on fatty acids was abolished, due to the restoration of peroxisome proliferator-activated receptor- $\gamma$  coactivator (PGC-1 $\alpha$ ) expression, which is involved in glucose oxidation [187]. Collectively, evidence suggests exercise can help restore healthy myocardial function in the insulin resistant states.

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is of increased interest due the growing popularity of GLP-1 receptor agonists (GLP-1RA) offered as weight loss and glucose control aids. These drugs profoundly affect lipid metabolism by promoting fatty acid oxidation and inducing lipolysis [188]. Although data on the effect of exercise with or without GLP-1RA administration on

lipid and glucose metabolism is scarce, one study has shown that the combination of both is superior to exercise alone on  $\beta$ -cell secretory function [189] in T2D. We have recently shown in rodents that combination of exercise with liraglutide is much more effective in improving muscle insulin sensitivity than either exercise or liraglutide alone in rats fed a HFD [115]. Importantly, GLP-1RA induces significant reduction of lean muscle mass in addition to loss of fat mass [190] and supplementing GLP-1RA treatment with exercise may be beneficial for the preservation of muscle mass. Further studies are clearly needed.

### Strengths and limitations


This review provides a comprehensive analysis of the intricate relationships among fatty acid metabolism, exercise-induced vascular adaptations, and insulin-mediated vascular changes, emphasizing their collective impact on vascular health and associated mechanisms in both healthy and insulin-resistant states. The review includes evidence from in vitro cell studies, in vivo rodent models, and human studies, enhancing its translational value and clinical relevance.

However, the limitations include a relatively limited focus on in-depth molecular mechanisms, as this is not the primary aim of the review. Additionally, while much of the evidence presented is based on preclinical studies, further research is necessary to corroborate these findings in human populations. Despite these limitations, the review offers valuable insights and guidance for future studies exploring the therapeutic potential of targeted exercise interventions and fatty acid-focused dietary strategies to improve vascular health.

### Conclusions and perspective

In conclusion, the intricate relationships and complex interplay among fatty acid metabolism, exercise training-induced vascular adaptation, and insulin-mediated vascular changes have a significant impact on vascular health, particularly in the context of metabolic disorders like obesity, T2D, and CVD (Fig. 3). Fatty acids, as key energy sources and signaling molecules, play essential roles in cellular homeostasis, but an excess or imbalance of certain types - especially SFAs - can disrupt normal metabolic pathways. This disruption can lead to vascular inflammation, endothelial dysfunction, and endothelial insulin resistance, all of which are major contributors to vascular dysfunction and disease. Conversely, PUFAs might offer protective effects on insulin sensitivity, reduce inflammation, and help preserve endothelial function. Therefore, optimizing fatty acid intake and balance through diet may be a critical factor in improving metabolic and vascular health.





**Fig. 3** Interplay of FFAs, insulin and exercise in the vasculature. Plasma FFAs lead to vascular dysfunction through increased vascular inflammation, insulin resistance, and remodeling. Insulin inhibits lipolysis and enhances synthesis of FFAs, reducing the amount of plasma FFAs. Exercise increases  $\beta$ -oxidation of FFAs and stimulates beneficial vascular adaptations, thereby combating endothelial dysfunction. (Abbreviations: FA, fatty acid; FFAs, free fatty acids)

Exercise, a well-established intervention for reducing T2D and CVD risk, exerts its beneficial effects by enhancing fatty acid oxidation, improving insulin sensitivity, and inducing beneficial vascular adaptation. Regular physical activity promotes favorable shifts in fatty acid metabolism, leading to reduced circulating FFAs and decreased ectopic lipid accumulation, thus reducing lipotoxicity, enhancing insulin action and mitigating vascular dysfunction. Exercise further strengthens vascular health through improved endothelial function, increased NO production, and reduced oxidative stress and inflammation. By modulating fatty acid utilization and improving insulin-mediated vasodilation and overall insulin sensitivity, exercise plays a crucial role in sustaining healthy vascular function.

Looking forward, further research is needed to clarify the mechanistic pathways linking specific fatty acids to vascular insulin resistance, and to understand how exercise may modulate these pathways differentially in the vasculature. Additionally, personalized exercise programs that consider individual fatty acid metabolic profiles could offer targeted benefits for patients with metabolic disorders. Investigating the long-term effects of combining exercise interventions with dietary adjustments to optimize fatty acid composition may further unveil comprehensive approaches to combat vascular diseases. By advancing our understanding of these interconnections, we can better address the dual challenges of metabolic

and cardiovascular health, improving outcomes for individuals affected by T2D and related conditions.

#### Abbreviations

CVD	Cardiovascular disease
ERK	Extracellular signal regulated kinase
ET-1	Endothelin 1
eNOS	Endothelial nitric oxide synthase
FFA	Free fatty acid
HFD	High fat diet
FMD	Flow-mediated dilation
IGF-1	Insulin like growth factor I
IKK $\beta$	Inhibitor of nuclear factor kappa B kinase $\beta$
JNK	C-Jun NH2-terminal kinase
MAPK	Mitogen-activated protein kinase
MUFA	Monounsaturated fatty acid
NF- $\kappa$ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
NO	Nitric oxide
PI3-K	Phosphatidylinositol 3-kinase
PKC	Protein kinase C
PUFA	Polyunsaturated fatty acid
ROS	Reactive oxygen species
SFA	Saturated fatty acid
T2D	Type 2 diabetes
VEGF	Vascular endothelial growth factor
VO <sub>2peak</sub>	Peak oxygen uptake

#### Author contributions

KCA and JL prepared Figs. 1, 2 and 3 and contributed to the main manuscript text. ZL wrote the main manuscript text. All authors reviewed the manuscript.

#### Funding

This work was supported by National Institutes of Health grants R01DK124344 and R01DK125330 (to Z.L.). KCA is supported by grant 5T32DK007646 (to the University of Virginia).

#### Data availability

No datasets were generated or analysed during the current study.

#### Declarations

#### Ethics approval

N/A.

#### Competing interests

The authors declare no competing interests.

Received: 31 October 2024 / Accepted: 26 December 2024

Published online: 07 January 2025

#### References

- Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and Cardiovascular diseases. *Circ Res*. 2020;126(11):1477–500.
- Love KM, Jahn LA, Hartline LM, Aylor KW, Liu Z. Impact of free fatty acids on vascular insulin responses across the arterial tree: a randomized crossover study. *J Clin Endocrinol Metab*. 2024;109(4):1041–50.
- Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. *Lancet*. 2021;398(10313):1803–10.
- Association AD. 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes-2025. *Diabetes Care*. 2025;48(Supplement 1):S207–38.
- Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. *Am J Physiol Endocrinol Metab*. 2011;301(2):E252–63.
- Liu J, Liu Z. Muscle insulin resistance and the inflamed microvasculature: fire from within. *Int J Mol Sci*. 2019;20(3):562.

7. Fu J, Yu MG, Li Q, Park K, King GL. Insulin's actions on vascular tissues: physiological effects and pathophysiological contributions to vascular complications of diabetes. *Mol Metab*. 2021;52:101236.
8. Love KM, Barrett EJ, Malin SK, Reusch JEB, Regensteiner JG, Liu Z. Diabetes pathogenesis and management: the endothelium comes of age. *J Mol Cell Biol*. 2021;13(7):500–12.
9. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. *Cell Metab*. 2012;15(5):635–45.
10. Yazıcı D, Demir S, Sezer H. Insulin resistance, obesity, and lipotoxicity. *Adv Exp Med Biol*. 2024;1460:391–430.
11. Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. *Diabetologia*. 2001;44(3):312–9.
12. Yang W, Jiang W, Guo S. Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes Mellitus. *Nutrients*. 2023;15(21).
13. Zheng C, Liu Z. Vascular function, insulin action, and exercise: an intricate interplay. *Trends Endocrinol Metabolism*. 2015;26(6):297–304.
14. Malin SK, Liu Z, Barrett EJ, Weltman A. Exercise resistance across the prediabetes phenotypes: impact on insulin sensitivity and substrate metabolism. *Reviews Endocr Metabol Disord*. 2016;17(1):81–90.
15. Yin M, Chen Z, Nassiss GP, Liu H, Li H, Deng J, et al. Chronic high-intensity interval training and moderate-intensity continuous training are both effective in increasing maximum fat oxidation during exercise in overweight and obese adults: a meta-analysis. *J Exerc Sci Fit*. 2023;21(4):354–65.
16. Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2020;16(10):545–55.
17. Barrett E, Eggleston E, Inyard A, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. *Diabetologia*. 2009;52(5):752–64.
18. Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. *Endocrinology*. 2005;146(11):4690–96.
19. Li G, Barrett EJ, Ko S-H, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. *Endocrinology*. 2009;150(8):3475–82.
20. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. *Am J Physiol Endocrinol Metab*. 2004;286(6):E896–901.
21. Dekker Nitert M, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I/insulin hybrid receptors in human endothelial cells. *Mol Cell Endocrinol*. 2005;229(1–2):31–7.
22. King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. *Science*. 1985;227(4694):1583–6.
23. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. *J Clin Invest*. 1996;98(4):894–8.
24. Zeng G, Nystrom FH, Ravichandran LV, Cong L-N, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. *Circulation*. 2000;101(13):1539–45.
25. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. *J Biol Chem*. 1991;266(34):23251–6.
26. Eringa EC, Stehouwer CDA, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. *Cardiovascular Res*. 2002;56(3):464–71.
27. Eringa EC, Stehouwer CDA, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. *Am J Physiol Heart Circ Physiol*. 2004;287(5):H2043–8.
28. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. *Endocr Rev*. 2007;28(5):463–91.
29. Kim J-a, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation*. 2006;113(15):1888–904.
30. Tamminen M, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Insulin-induced decreases in aortic wave reflection and central systolic pressure are impaired in type 2 diabetes. *Diabetes Care*. 2002;25(12):2314–9.
31. Jahn LA, Hartline L, Rao N, Logan B, Kim JJ, Aylor K, et al. Insulin enhances endothelial function throughout the arterial tree in healthy but not metabolic syndrome subjects. *J Clin Endocrinol Metab*. 2016;101(3):1198–206.
32. Tan AWK, Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, et al. GLP-1 and insulin recruit muscle microvasculature and dilate conduit artery individually but not additively in healthy humans. *J Endocr Soc*. 2018;2(2):190–206.
33. Heiston EM, Liu Z, Ballantyne A, Kranz S, Malin SK. A single bout of exercise improves vascular insulin sensitivity in adults with obesity. *Obes (Silver Spring Md)*. 2021;29(9):1487–96.
34. Shadwick RE. Mechanical design in arteries. *J Exp Biol*. 1999;202(23):3305–13.
35. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest*. 1996;97(11):2601–10.
36. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. *Hypertension*. 1999;33(5):1118–22.
37. Tamminen M, Seppala-Lindroos A, Yki-Järvinen H. Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. *J Clin Endocrinol Metab*. 2001;86(11):5262–8.
38. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. *Hypertension*. 2000;36(3):312–8.
39. Baron AD. Hemodynamic actions of insulin. *Am J Physiol Endocrinol Metab*. 1994;267(2):E187–202.
40. Baron AD, Steinberg H, Brechtel G, Johnson A. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. *Am J Physiol Endocrinol Metab*. 1994;266(2):E248–53.
41. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. *J Clin Invest*. 1994;94(3):1172–9.
42. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. *Diabetes*. 2000;49(7):1231–8.
43. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. *J Clin Invest*. 1997;100(5):1230–9.
44. Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. *Diabetes*. 2004;53(6):1418–23.
45. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. *Am J Physiol Endocrinol Metab*. 2003;285(1):E123–9.
46. Gokce N, Keaney Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. *J Am Coll Cardiol*. 2003;41(10):1769–75.
47. Thijssen DHJ, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *Am J Physiol Heart Circ Physiol*. 2011;300(1):H2–12.
48. Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. *J Diabetes*. 2020;12(7):488–98.
49. Love KM, Jahn LA, Hartline LM, Patrie JT, Barrett EJ, Liu Z. Insulin-mediated muscle microvascular perfusion and its phenotypic predictors in humans. *Sci Rep*. 2021;11(1):11433.
50. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Järvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. *Diabetes*. 1999;48(4):821–7.
51. Henry RM, Ferreira I, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; the Hoorn Study. *Atherosclerosis*. 2004;174(1):49–56.
52. Naka KK, Papanthanasidou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S, et al. Determinants of vascular function in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2012;11:127.
53. Westerbacka J, Seppala-Lindroos A, Yki-Järvinen H. Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. *J Clin Endocrinol Metab*. 2001;86(11):5262–8.
54. Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MADH, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. *Circulation*. 2006;113(5):657–63.

55. Stehouwer CDA, Henry RMA, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. *Diabetologia*. 2008;51(4):527–39.
56. Webb DR, Khunti K, Silverman R, Gray LJ, Srinivasan B, Lacy PS, et al. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. *Diabetologia*. 2010;53(6):1190–8.
57. Jahn LA, Hartline L, Liu Z, Barrett EJ. Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome. *Am J Physiol Endocrinol Metab*. 2022;322(2):E173–80.
58. Wang N, Tan AWK, Jahn LA, Hartline L, Patrie JT, Lin S, et al. Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance. *Diabetes Care*. 2019;43(3):634–42.
59. Sørensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, et al. Prediabetes and type 2 diabetes are associated with generalized microvascular dysfunction: the Maastricht Study. *Circulation*. 2016;134(18):1339–52.
60. Clerk LH, Vincent MA, Barrett EJ, Lankford MF, Lindner JR. Skeletal muscle capillary responses to insulin are abnormal in late-stage diabetes and are restored by angiotensin-converting enzyme inhibition. *Am J Physiol Endocrinol Metab*. 2007;293(6):E1804–9.
61. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark ADH, Clark MG. Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. *Diabetes*. 2002;51(12):3492–8.
62. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. *Circulation*. 2001;103(13):1734–9.
63. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. *Diabetes*. 2006;55(5):1436–42.
64. Zhao L, Fu Z, Wu J, Aylor Kevin W, Barrett Eugene J, Cao W, et al. Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity. *Clin Sci*. 2015;129(12):1025–36.
65. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. *Arterioscler Thromb Vasc Biol*. 2008;28(11):1982–8.
66. Jiang ZY, Lin Y-W, Clemont A, Feener EP, Hein KD, Igarashi M, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. *J Clin Invest*. 1999;104(4):447–57.
67. Kim J-a, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. *Arterioscler Thromb Vasc Biol*. 2005;25(5):889–91.
68. Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. *Am J Physiol Heart Circ Physiol*. 2005;289(2):H813–22.
69. Zhang D, Wei Y, Huang Q, Chen Y, Zeng K, Yang W et al. Important Hormone Regulating Lipid Metabolism Molecules. 2022;27(20).
70. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*. 2001;414(6865):799–806.
71. Liu Z. Cellular basis of insulin resistance: A tale of the microvasculature. In: Ulloa-Aguirre A, Tao Y-X, editors. *Cellular Endocrinology in Health and Disease*. 2nd edition ed: Elsevier; 2020. pp. 315–31.
72. Himanshu D, Ali W, Wamique M. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. *J Diabetes Metab Disord*. 2020;19(2):1959–66.
73. Liao GZ, Liu HH, He CH, Feng JY, Zhuang XF, Wang JX, et al. Free fatty acids: independent predictors of long-term adverse cardiovascular outcomes in heart failure patients. *Lipids Health Dis*. 2024;23(1):343.
74. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic  $\beta$  cells through GPR40. *Nature*. 2003;422(6928):173–6.
75. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. *Diabetologia*. 2003;46(10):1297–312.
76. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. *J Clin Invest*. 1997;100(2):398–403.
77. Warnotte C, Nenquin M, Henquin JC. Unbound rather than total concentration and saturation rather than unsaturation determine the potency of fatty acids on insulin secretion. *Mol Cell Endocrinol*. 1999;153(1–2):147–53.
78. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. *Endocrinology*. 1990;127(4):1580–9.
79. Elks ML. Chronic perfusion of rat islets with palmitate suppresses glucose-stimulated insulin release. *Endocrinology*. 1993;133(1):208–14.
80. Mason TM, Goh T, Tchpashvili V, Sandhu H, Gupta N, Lewis GF, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. *Diabetes*. 1999;48(3):524–30.
81. Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. *Diabetologia*. 1995;38(11):1295–9.
82. Reaven GM, Chen YD. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. *Am J Med*. 1988;85(5a):106–12.
83. Poitout V, Robertson RP. Glucolipotoxicity. Fuel excess and  $\beta$ -Cell dysfunction. *Endocr Rev*. 2008;29(3):351–66.
84. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. *J Clin Invest*. 1995;96(3):1261–8.
85. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. *J Clin Invest*. 1994;93(6):2438–46.
86. Itani SJ, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I $\kappa$ B $\alpha$ . *Diabetes*. 2002;51(7):2005–11.
87. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unraveling the mechanism. *Lancet*. 2010;375(9733):2267–77.
88. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem*. 2004;279(31):32345–53.
89. Kennedy A, Martinez K, Chuang CC, LaPoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. *J Nutr*. 2009;139(1):1–4.
90. Alkhatieb H, Chabowski A, Glatz JFC, Luiken JFP, Bonen A. Two phases of palmitate-induced insulin resistance in skeletal muscle: impaired GLUT4 translocation is followed by a reduced GLUT4 intrinsic activity. *Am J Physiol Endocrinol Metab*. 2007;293(3):E783–93.
91. Holland WL, Brozinick JT, Wang L-P, Hawkins ED, Sargent KM, Liu Y, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. *Cell Metab*. 2007;5(3):167–79.
92. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. *J Clin Invest*. 2011;121(5):1858–70.
93. Palomer X, Pizarro-Delgado J, Barroso E, Vázquez-Carrera M. Palmitic and oleic acid: the Yin and Yang of fatty acids in type 2 diabetes Mellitus. *Trends Endocrinol Metab*. 2018;29(3):178–90.
94. Esposito K, Maiorino MI, Ceriello A, Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. *Diabetes Res Clin Pract*. 2010;89(2):97–102.
95. Martínez-González MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, Basterra-Gortari FJ, Beunza JJ, Vazquez Z, et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ*. 2008;336(7657):1348–51.
96. Salas-Salvadó J, Bulló M, Babio N, Martínez-González M, Ibarrola-Jurado N, Basora J, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care*. 2011;34(1):14–9.
97. Galbo T, Perry RJ, Jurczak MJ, Camporez J-PG, Alves TC, Kahn M, et al. Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivo. *Proc Natl Acad Sci*. 2013;110(31):12780–5.
98. Leung SWS, Shi Y. The glycolytic process in endothelial cells and its implications. *Acta Pharmacol Sin*. 2022;43(2):251–9.
99. Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in Health and Disease. *Cell Metab*. 2019;30(3):414–33.
100. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. *Cell*. 2013;154(3):651–63.
101. Harjes U, Kalucka J, Carmeliet P. Targeting fatty acid metabolism in cancer and endothelial cells. *Crit Rev Oncol Hematol*. 2016;97:15–21.
102. Kazantzis M, Stahl A. Fatty acid transport proteins, implications in physiology and disease. *Biochim Biophys Acta*. 2012;1821(5):552–7.

103. Liu B, Dai Z. Fatty acid metabolism in endothelial cell. *Genes (Basel)*. 2022;13(12).
104. Mallick R, Duttaroy AK. Modulation of endothelium function by fatty acids. *Mol Cell Biochem*. 2022;477(1):15–38.
105. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. *Diabetes Care*. 1991;14(9):839–55.
106. Kuo A, Lee MY, Sessa WC. Lipid Droplet Biogenesis and function in the endothelium. *Circ Res*. 2017;120(8):1289–97.
107. Chai W, Liu Z. p38 mitogen-activated protein kinase mediates palmitate-induced apoptosis but not inhibitor of nuclear factor- $\kappa$ B degradation in human coronary artery endothelial cells. *Endocrinology*. 2007;148(4):1622–8.
108. Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. *J Clin Endocrinol Metab*. 2011;96(2):438–46.
109. Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. *J Clin Endocrinol Metab*. 2009;94(9):3543–9.
110. Rask-Madsen C, Li Q, Freund B, Feather D, Abramov R, Wu IH, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. *Cell Metabol*. 2010;11(5):379–89.
111. Ko S-H, Cao W, Liu Z. Hypertension management and microvascular insulin resistance in diabetes. *Curr Hypertens Rep*. 2010;12(4):243–51.
112. Liu Z. The vascular endothelium in diabetes and its potential as a therapeutic target. *Rev Endocr Metab Disord*. 2013;14(1):1–3.
113. Clerk LH, Rattigan S, Clark MG. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. *Diabetes*. 2002;51(4):1138–45.
114. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. *Endocrinology*. 2007;148(1):160–5.
115. Liu J, Aylor KW, Liu Z. Liraglutide and exercise synergistically attenuate vascular inflammation and enhance metabolic insulin action in early diet-induced obesity. *Diabetes*. 2023;72(7):918–31.
116. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J Biol Chem*. 2002;277(52):50230–6.
117. Zhang H, Dellspinger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. *Basic Res Cardiol*. 2012;107(1):237.
118. Jiao P, Ma J, Feng B, Zhang H, Diehl JA, Chin YE, et al. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKK $\beta$  pathways. *Obes (Silver Spring Md)*. 2011;19(3):483–91.
119. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. *Diabetes*. 2005;54(Suppl 2):S73–8.
120. Shi H, Kokoeva MV, Inouye K, Tzamelis I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. *J Clin Invest*. 2006;116(11):3015–25.
121. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes*. 2000;49(11):1939–45.
122. Khapchaev AY, Vorotnikov AV, Antonova OA, Samsonov MV, Shestakova EA, Sklyanik IA et al. Shear Stress and the AMP-Activated protein kinase independently protect the vascular endothelium from Palmitate Lipotoxicity. *Biomedicines*. 2024;12(2).
123. Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. *Diabetes Care*. 2011;34(7):1634–8.
124. Gavin TP, Stallings HW, Zwetsloot KA, Westerkamp LM, Ryan NA, Moore RA, et al. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. *J Appl Physiol*. 2005;98(1):315–21.
125. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. *J Clin Invest*. 1987;80(2):415–24.
126. Chung AWY, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiotensin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. *Circ Res*. 2006;99(2):140–8.
127. Frisbee JC. Obesity, insulin resistance, and microvessel density. *Microcirculation*. 2007;14(4):289–98.
128. Solomon TPJ, Haus JM, Li Y, Kirwan JP. Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability. *J Clin Endocrinol Metab*. 2011;96(5):1377–84.
129. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. *Nat Rev Mol Cell Biol*. 2006;7(5):359–71.
130. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: Differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. *Circ Res*. 2007;101(9):948–56.
131. Chai W, Fu Z, Aylor KW, Barrett EJ, Liu Z. Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats. *Am J Physiol Endocrinol Metab*. 2016;311(3):E640–8.
132. Artwohl M, Roden M, Waldhäusl W, Freudenthaler A, Baumgartner-Parzer SM. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. *FASEB J*. 2004;18(1):146–8.
133. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. *Diabetes Care*. 1997;20(4):537–44.
134. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393–403.
135. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343–50.
136. Roque FR, Hernanz R, Saldañas M, Briones AM. Exercise training and cardiometabolic diseases: focus on the vascular system. *Curr Hypertens Rep*. 2013;15(3):204–14.
137. Green DJ, Hopman MT, Padilla J, Laughlin MH, Thijssen DH. Vascular adaptation to Exercise in humans: role of hemodynamic stimuli. *Physiol Rev*. 2017;97(2):495–528.
138. Tao X, Chen Y, Zhen K, Ren S, Lv Y, Yu L. Effect of continuous aerobic exercise on endothelial function: a systematic review and meta-analysis of randomized controlled trials. *Front Physiol*. 2023;14:1043108.
139. Ashor AW, Lara J, Siero M, Celis-Morales C, Mathers JC. Effects of exercise modalities on arterial stiffness and wave reflection: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE*. 2014;9(10):e110034.
140. Rowley NJ, Dawson EA, Birk GK, Cable NT, George K, Whyte G, et al. Exercise and arterial adaptation in humans: uncoupling localized and systemic effects. *J Appl Physiol (Bethesda Md: 1985)*. 2011;110(5):1190–5.
141. Rowley NJ, Dawson EA, Hopman MT, George KP, Whyte GP, Thijssen DH, et al. Conduit diameter and wall remodeling in elite athletes and spinal cord injury. *Med Sci Sports Exerc*. 2012;44(5):844–9.
142. Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, et al. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. *Circulation*. 2003;107(25):3152–8.
143. Thijssen DH, Dawson EA, van den Munckhof IC, Tinken TM, den Drijver E, Hopkins N, et al. Exercise-mediated changes in conduit artery wall thickness in humans: role of shear stress. *Am J Physiol Heart Circ Physiol*. 2011;301(1):H241–6.
144. Green DJ, Fowler DT, O'Driscoll JG, Blanksby BA, Taylor RR. Endothelium-derived nitric oxide activity in forearm vessels of tennis players. *J Appl Physiol (Bethesda Md: 1985)*. 1996;81(2):943–8.
145. Kingwell BA, Sherrard B, Jennings GL, Dart AM. Four weeks of cycle training increases basal production of nitric oxide from the forearm. *Am J Physiol*. 1997;272(3 Pt 2):H1070–7.
146. Bank AJ, Shammas RA, Mullen K, Chuang PP. Effects of short-term forearm exercise training on resistance vessel endothelial function in normal subjects and patients with heart failure. *J Card Fail*. 1998;4(3):193–201.
147. Higashi Y, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. *Circulation*. 1999;100(11):1194–202.
148. Maiorana A, O'Driscoll G, Cheetham C, Dembo L, Stanton K, Goodman C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. *J Am Coll Cardiol*. 2001;38(3):860–6.
149. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves

- exercise capacity in patients with chronic heart failure. *Circulation*. 1998;98(24):2709–15.
150. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. *Physiol Rev*. 2008;88(3):1009–86.
151. Scognamiglio R, Negut C, de Kreutzenberg SV, Palisi M, Tiengo A, Avogaro A. Abnormal myocardial perfusion and contractile recruitment during exercise in type 1 diabetic patients. *Clin Cardiol*. 2005;28(2):93–9.
152. Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-Poi H, et al. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. *Am J Physiol Endocrinol Metab*. 2006;290(6):E1191–7.
153. Russell RD, Hu D, Greenaway T, Blackwood SJ, Dwyer RM, Sharman JE, et al. Skeletal muscle microvascular-linked improvements in glycemic control from resistance training in individuals with type 2 diabetes. *Diabetes Care*. 2017;40(9):1256–63.
154. Cocks M, Shaw CS, Shepherd SO, Fisher JP, Ranasinghe A, Barker TA, et al. Sprint interval and moderate-intensity continuous training have equal benefits on aerobic capacity, insulin sensitivity, muscle capillarisation and endothelial eNOS/NAD(P)h oxidase protein ratio in obese men. *J Physiol*. 2016;594(8):2307–21.
155. Inyard AC, Chong DG, Klibanov AL, Barrett EJ. Muscle contraction, but not insulin, increases microvascular blood volume in the presence of free fatty acid-induced insulin resistance. *Diabetes*. 2009;58(11):2457–63.
156. Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG, Rattigan S. TNF- $\alpha$  acutely inhibits vascular effects of physiological but not high insulin or contraction. *Am J Physiol Endocrinol Metab*. 2003;285(3):E654–60.
157. Wheatley CM, Rattigan S, Richards SM, Barrett EJ, Clark MG. Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats. *Am J Physiol Endocrinol Metab*. 2004;287(4):E804–9.
158. Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. *Microcirculation*. 2014;21(4):301–14.
159. Saltin B. Capacity of blood flow delivery to exercising skeletal muscle in humans. *Am J Cardiol*. 1988;62(8):E30–5.
160. Hudlicka O, Brown MD. Adaptation of skeletal muscle microvasculature to increased or decreased blood flow: role of shear stress, nitric oxide and vascular endothelial growth factor. *J Vasc Res*. 2009;46(5):504–12.
161. Hoier B, Rufener N, Bøjsen-Møller J, Bangsbo J, Hellsten Y. The effect of passive movement training on angiogenic factors and capillary growth in human skeletal muscle. *J Physiol*. 2010;588(Pt 19):3833–45.
162. Olfert IM, Howlett RA, Tang K, Dalton ND, Gu Y, Peterson KL, et al. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice. *J Physiol*. 2009;587(8):1755–67.
163. Castorena CM, Arias EB, Sharma N, Cartee GD. Postexercise improvement in insulin-stimulated glucose uptake occurs concomitant with greater AS160 phosphorylation in muscle from normal and insulin-resistant rats. *Diabetes*. 2014;63(7):2297–308.
164. Newsom SA, Everett AC, Hinko A, Horowitz JF. A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adults. *Diabetes Care*. 2013;36(9):2516–22.
165. Clark MG, Rattigan S, Clerk LH, Vincent MA, Clark ADH, Youd JM, et al. Nutritive and non-nutritive blood flow: rest and exercise. *Acta Physiol Scand*. 2000;168(4):519–30.
166. Clark MG. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. *Am J Physiol Endocrinol Metab*. 2008;295(4):E732–50.
167. Barrett EJ, Liu Z. The endothelial cell: an early responder in the development of insulin resistance. *Rev Endocr Metab Disord*. 2013;14(1):21–7.
168. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, et al. Diabetic microvascular disease: an Endocrine Society scientific statement. *J Clin Endocrinol Metab*. 2017;102(12):4343–410.
169. Inyard AC, Clerk LH, Vincent MA, Barrett EJ. Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake. *Diabetes*. 2007;56(9):2194–200.
170. Holmäng A, Mimura K, Björntorp P, Lsönroth P. Interstitial muscle insulin and glucose levels in normal and insulin-resistant Zucker rats. *Diabetes*. 1997;46(11):1799–804.
171. Hargreaves M, Spriet LL. Skeletal muscle energy metabolism during exercise. *Nat Metab*. 2020;2(9):817–28.
172. Brun JF, Myzja J, Varlet-Marie E, Raynaud de Mauverger E, Mercier J. Beyond the calorie paradigm: taking into Account in Practice the Balance of Fat and Carbohydrate Oxidation during Exercise? *Nutrients*. 2022;14(8).
173. Brooks GA. Importance of the 'crossover' concept in exercise metabolism. *Clin Exp Pharmacol Physiol*. 1997;24(11):889–95.
174. Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Ender E, et al. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. *Am J Physiol*. 1993;265(3 Pt 1):E380–91.
175. van Loon LJ, Greenhaff PL, Constantin-Teodosiu D, Saris WH, Wagenmakers AJ. The effects of increasing exercise intensity on muscle fuel utilisation in humans. *J Physiol*. 2001;536(Pt 1):295–304.
176. Furrer R, Hawley JA, Handschin C. The molecular athlete: exercise physiology from mechanisms to medals. *Physiol Rev*. 2023;103(3):1693–787.
177. Achten J, Jeukendrup AE. Optimizing fat oxidation through exercise and diet. *Nutrition*. 2004;20(7–8):716–27.
178. Mogensen M, Vind BF, Højlund K, Beck-Nielsen H, Sahlin K. Maximal lipid oxidation in patients with type 2 diabetes is normal and shows an adequate increase in response to aerobic training. *Diabetes Obes Metab*. 2009;11(9):874–83.
179. Fritzen AM, Lundsgaard AM, Kiens B. Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise. *Nat Rev Endocrinol*. 2020;16(12):683–96.
180. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. *Am J Physiol Endocrinol Metab*. 2008;295(5):E1009–17.
181. Lundsgaard AM, Fritzen AM, Nicolaisen TS, Carl CS, Sjøberg KA, Raun SH, et al. Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation. *J Lipid Res*. 2020;61(1):10–9.
182. Alkahtani SA, King NA, Hills AP, Byrne NM. Effect of interval training intensity on fat oxidation, blood lactate and the rate of perceived exertion in obese men. *Springerplus*. 2013;2:532.
183. Langlois A, Forterre A, Pinget M, Bouzakri K. Impact of moderate exercise on fatty acid oxidation in pancreatic  $\beta$ -cells and skeletal muscle. *J Endocrinol Invest*. 2021;44(9):1815–25.
184. de Matos MA, Vieira DV, Pinhal KC, Lopes JF, Dias-Peixoto MF, Pauli JR, et al. High-intensity interval training improves markers of oxidative metabolism in skeletal muscle of individuals with obesity and insulin resistance. *Front Physiol*. 2018;9:1451.
185. Shi X, Qiu H. New insights Into Energy substrate utilization and metabolic remodeling in Cardiac physiological adaptation. *Front Physiol*. 2022;13:831829.
186. Nirengi S, Peres Valgas da Silva C, Stanford KI. Disruption of energy utilization in diabetic cardiomyopathy: a mini review. *Curr Opin Pharmacol*. 2020;54:82–90.
187. Wang SY, Zhu S, Wu J, Zhang M, Xu Y, Xu W, et al. Exercise enhances cardiac function by improving mitochondrial dysfunction and maintaining energy homeostasis in the development of diabetic cardiomyopathy. *J Mol Med (Berl)*. 2020;98(2):245–61.
188. Yarıbeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. The impact of Incretin-based medications on lipid metabolism. *J Diabetes Res*. 2021;2021:1815178.
189. Ingersen A, Schmücker M, Alexandersen C, Graungaard B, Thorngreen T, Borch J, et al. Effects of Aerobic Training and Semaglutide Treatment on pancreatic  $\beta$ -Cell secretory function in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2023;108(11):2798–811.
190. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. *Lancet Diabetes Endocrinology*. 2024;12(11):785–787.

## Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.